Israel Englander Biomarin Pharmaceutical Inc Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Millennium Management LLC holds 31,500 shares of BMRN stock, worth $2.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,500

Previous 1,168,355 97.3%

Holding current value

$2.36 Million

Previous $113 Million 97.56%

% of portfolio

0.0%

Previous 0.05%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $92.9 Million - $110 Million	1,108,824 Added 94.9%	2,277,179 $199 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $63.9 Million - $82.5 Million	837,948 Added 253.61%	1,168,355 $113 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $68,650 - $79,437	792 Added 0.24%	330,407 $28.6 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $40 Million - $53.5 Million	-455,835 Reduced 58.03%	329,615 $32.1 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $88.1 Million - $118 Million	-1,088,822 Reduced 58.09%	785,450 $81.3 Million

Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $28.6 Million - $33.8 Million	348,269 Added 22.82%	1,874,272 $159 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $16 Million - $19.5 Million	224,011 Added 17.21%	1,526,003 $126 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $44.1 Million - $55.1 Million	593,956 Added 83.89%	1,301,992 $100 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $10.1 Million - $12.8 Million	-140,452 Reduced 16.55%	708,036 $62.6 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $60.4 Million - $69 Million	807,552 Added 1972.72%	848,488 $65.6 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $15.4 Million - $17.3 Million	-204,255 Reduced 83.3%	40,936 $3.42 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $16.9 Million - $20.5 Million	-226,302 Reduced 48.0%	245,191 $18.5 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $2.73 Million - $3.39 Million	-37,571 Reduced 7.38%	471,493 $41.3 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $26.9 Million - $49.1 Million	374,732 Added 278.96%	509,064 $38.7 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $7.49 Million - $11.7 Million	-94,130 Reduced 41.2%	134,332 $16.6 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $27.2 Million - $36.9 Million	-381,353 Reduced 62.54%	228,462 $19.3 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $23 Million - $30.9 Million	357,766 Added 141.94%	609,815 $51.6 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $10.7 Million - $13.6 Million	-159,380 Reduced 38.74%	252,049 $17 Million
Q2 2019 Aug 15, 2019	BUY	$80.35 - $93.9 $20.1 Million - $23.4 Million	249,664 Added 154.34%	411,429 $35.2 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $1.05 Million - $1.23 Million	-13,113 Reduced 7.5%	161,765 $1.19 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $5.77 Million - $6.76 Million	68,586 Added 64.53%	174,878 $15.5 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $18.3 Million - $24.2 Million	-228,550 Reduced 68.26%	106,292 $9.05 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $23.9 Million - $26.9 Million	-254,808 Reduced 43.21%	334,842 $32.5 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $4.24 Million - $5.52 Million	-55,750 Reduced 8.64%	589,650 $55.5 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $818,331 - $975,949	10,536 Added 1.66%	645,400 $52.3 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $12.9 Million - $15.2 Million	160,132 Added 33.73%	634,864 $56.6 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $38.3 Million - $45.1 Million	474,732	474,732 $44.2 Million

Others Institutions Holding BMRN

# of Institutions

621

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.9B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account